Latest Breaking News On - Jinzij wu - Page 2 : comparemela.com

Ascletis Announces Poster Presentations at AASLD Annual Meeting 2023 Including a Late-Breaking Abstract of Interim Results from Phase IIb Expansion Cohort of ASC22 for Functional Cure of CHB

/PRNewswire/ Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") today announces late-breaking abstract poster presentation of interim results from Phase IIb.

China
Shaoxing
Zhejiang
Germany
Italy
United-kingdom
Japan
France
Hangzhou
Hong-kong
Spain
United-states

Dr. Jinzi J. Wu Presents at the 10th International Workshop on HBV Cure 2023

/PRNewswire/ Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") today announces that Dr. Jinzi J. Wu, Founder, Chairman and CEO of Ascletis was invited to attend.

United-states
Shaoxing
Zhejiang
China
Hangzhou
Massachusetts
Hong-kong
Boston
Toronto
Ontario
Canada
University-of-hong-kong

Ascletis Announces Poster Presentation of Phase II Study Topline Results of FASN Inhibitor ASC40 for Treatment of Acne at EADV Congress 2023

Ascletis Announces Poster Presentation of Phase II Study Topline Results of FASN Inhibitor ASC40 for Treatment of Acne at EADV Congress 2023
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

China
Hangzhou
Zhejiang
Hong-kong
Huashan
Henan
Germany
Berlin
Shaoxing
Jinzij-wu
Leihong-xiang
Sagimet-biosciences-inc

Ascletis Announces Positive Interim Data from the Phase IIb Expansion Cohort of ASC22 (Envafolimab) for Chronic Hepatitis B Functional Cure

/PRNewswire/ Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") today announces positive interim data from the Phase IIb expansion cohort (the "Expansion.

Hangzhou
Zhejiang
China
Shaoxing
United-states
Hong-kong
American
Jinzij-wu
Prnewswire-ascletis-pharma-inc
Ascletis-pharma-inc
Hong-kong-stock-exchange

Ascletis Announces Completion of Enrollment of 120 Patients in the Phase III Clinical Trial of FASN Inhibitor ASC40 Combined with Bevacizumab for Treatment of Recurrent Glioblastoma

/PRNewswire/ Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") today announces the completion of enrollment of 120 patients in the Phase III registration.

Shaoxing
Zhejiang
China
Hong-kong
United-states
Hangzhou
Acta-neuropathol
Jinzij-wu
Hong-kong-stock-exchange
Prnewswire-ascletis-pharma-inc
World-health-organization
Ascletis-pharma-inc